Home » Business News » 2011 » December » December 14, 2011

MagForce Signs Letter of Intent with Leading Russian Medical Product Distribution Company Delrus

December 14, 2011 - Berlin

MagForce AG /

MagForce Signs Letter of Intent with Leading Russian Medical ProductDistribution Company Delrus

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

* Plans outlined for NanoTherm® therapy market entry in Russia

* Financial and professional support for approval in Russia

* First step for internationalization of NanoTherm® therapy

MagForce AG (XETRA: MF6), a leading medicaltechnology company focusing on nanomedicine in oncology and Delrus Inc., aleading Russian medical product distribution company, announced today thesigning of a Letter of Intent (LOI) between the two companies. The LOIoutlinesa collaboration focusing on an exclusive distribution agreement forNanoTherm®therapy in the Russian Federation and Kazakhstan. The LOI includes Delrus'financial and professional support for the regulatory approval ofNanoTherm®therapy in brain tumors and other indications in Russia, includingpancreaticand Prostate cancer.

Delrus is one of the largest and most established distributors for medicalproducts in Russia, working with partners like Johnson & Johnson, 3M, NihonKohden, Fresenius Kabi, and many other medical products manufacturers.Withmore than 2500 employees, the company has an extensive distribution andservicenetwork to support their marketing activities, which enables them to notonlyintroduce new products and technologies to the market, but also supporttheirusage and expansion. The Russian market is especially interesting forMagForcesince it provides access to a population of 160 million people.

"This year Delrus is celebrating its twentieth anniversary as companyand itsongoing commitment to bring the most modern and advanced technologiesto theRussian healthcare system. Our motto, "progress in the name of life,"reflectsthe very promising potential we see in a collaboration with MagForce," saidJulyMagadeev, President of Delrus. "We look forward to the opportunity tobringnanomedicine in oncology to the medical market in Russia andKazakhstan andprofessionally support its usage among oncology specialists and inhospitals."

"I am extremely pleased that we are working together with Delrus toestablish acomprehensive collaboration to distribute NanoTherm® therapy inRussia andKazakhstan," said Dr. Andreas Jordan, Founder and member of the ExecutiveBoardat MagForce. "Their experience and excellent track record open upsignificantopportunities for MagForce in Central and Eastern European markets."


MagForce AG is a leading medical technology company focusing onnanomedicine inoncology. The company's proprietary procedure, NanoTherm® therapy,enables thetargeted treatment of solid tumors through the intratumoral generation ofheatvia activation of magnetic nanoparticles. NanoTherm®, NanoPlan®,andNanoActivator™ are components of the therapy and have received EU-wideregulatory approval as medical devices for the treatment of brain tumors.MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForceAG inselected countries. For more information, please visit


DELRUS, founded in 1991 with currently more than 2500 employees, is aninternational science and industry holding company maintaining partnershiprelations with medical product manufacturers in 30 countries. The company,amongleaders in the Russian market for medical goods and disposables, is activeinthe supply of medical institutions. Delrus has regional affiliates in the80largest cities of Russia, Belarus, Tajikistan, Kazakhstan, Kyrgyzstan,Uzbekistan, Azerbajan, and the Ukraine. For more information please


This release may containforward-looking statements and information which may beidentified by formulations using terms such as "expects", "aims","anticipates","intends", "plans", "believes", "seeks", "estimates" or "will". Suchforward-looking statements are based on our current expectations andcertain assumptionswhich may be subject to a variety of risks and uncertainties. The resultsactually achieved by MagForce AG may substantially differ from theseforward-looking statements. MagForce AG assumes no obligation to updatetheseforward-looking statements or to correct them in case of developments,which differ fromthose, anticipated.

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.


Stacy Wiedenmann
Director Investor Relations & Corporate Communications
Magforce AG
Max-Dohrn-Str. 8
10589 Berlin
T +49 30 308 380 31
F +49 30 308 380 99
M +49 151 12000 722
email: Email Contact


Comment on this story